Eating on GLP-1 · Article

Ozempic or Mounjaro With Type 2 Diabetes: What to Eat and What Changes

What to eat on Ozempic or Mounjaro with type 2 diabetes: low blood sugar, fruit, metformin, sick days and what to ask your doctor, per the US labels and the ADA.

Written by
Published
Next review
Sources
19 primary

No clinical review. No advertising from drug companies and no affiliate links.How we work

With type 2 diabetes, what you eat on Ozempic or Mounjaro looks a lot like what works for anyone on these medications: small, regular meals, protein, vegetables, beans, whole fruit and little added sugar. What changes is low blood sugar (hypoglycemia). The real risk shows up mainly if you also use insulin or a sulfonylurea, and that’s exactly when eating much less than before matters. It also pays to have a plan for days with nausea or vomiting.

In 30 seconds

  • On the drug alone, severe lows were rare: no severe hypoglycemia in the monotherapy trials of Ozempic or Mounjaro13.
  • With insulin or a sulfonylurea the risk goes up, and the US labels tell prescribers to consider reducing the insulin or sulfonylurea dose when starting the GLP-1 medication123. Your prescriber decides.
  • The ADA defines level 1 hypoglycemia as glucose under 70 mg/dL (3.9 mmol/L) and, for most people, describes treatment with 15 g of carbohydrate and a recheck 15 minutes later[12].
  • The ADA sets no ideal split of carbohydrate, protein and fat for people with diabetes; it asks for at least 14 g of fiber per 1,000 kcal and water instead of sugary drinks, juice included[11].
  • Whole fruit is in. An orange has about 10 times the fiber of a glass of orange juice with nearly the same carbohydrate[19].
  • Metformin rarely causes low blood sugar by itself, but it can happen if you don’t eat enough[10].

On October 5, 2026, I checked the current US labels and Medication Guides on DailyMed for Ozempic, Rybelsus and Ozempic tablets and Mounjaro, plus a metformin label, and read them next to the American Diabetes Association’s Standards of Care in Diabetes—2026, the NIDDK (the NIH institute for diabetes) and the 2025 joint advisory on nutrition and GLP-1 therapy. The EU prescribing information appears only where it adds something. The general eating plan is in what to eat on GLP-1 medications; this page covers what’s specific to diabetes.

Which GLP-1 medications are approved for type 2 diabetes in the US

Section 1 of each US label sets out different approved uses (the basics are in what are GLP-1 medications):

Medicine Active ingredient Form US indication
Ozempic[1] Semaglutide Weekly injection Blood sugar control in adults with type 2 diabetes, with diet and exercise; also lowers the risk of major cardiovascular events (with established heart disease) and of kidney disease worsening, kidney failure and cardiovascular death (with chronic kidney disease)
Rybelsus and Ozempic tablets[2] Semaglutide Daily tablet Blood sugar control in adults with type 2 diabetes; also lowers the risk of major cardiovascular events in those at high risk
Mounjaro[3] Tirzepatide Weekly injection Blood sugar control in type 2 diabetes from age 10; also lowers the risk of major cardiovascular events in adults at high risk
Victoza[4] Liraglutide Daily injection Blood sugar control in type 2 diabetes from age 10; cardiovascular risk reduction in adults with established cardiovascular disease
Trulicity[5] Dulaglutide Weekly injection Blood sugar control in type 2 diabetes from age 10; cardiovascular risk reduction in adults with established cardiovascular disease or multiple risk factors
Wegovy[6] Semaglutide Weekly injection or daily tablet Weight reduction and maintenance; cardiovascular risk reduction in adults with heart disease and obesity or overweight; MASH, a liver disease (injection only)
Zepbound[7] Tirzepatide Weekly injection Weight reduction and maintenance; moderate to severe obstructive sleep apnea in adults with obesity

Neither Wegovy nor Zepbound lists blood sugar control among its uses67; in the EU, Mounjaro covers both type 2 diabetes and weight management[9]. The pairs are compared in Ozempic vs Wegovy, Mounjaro vs Zepbound and Ozempic vs Mounjaro.

The tablets come with an eating rule of their own: one tablet in the morning on an empty stomach with up to 4 ounces of water, then at least 30 minutes before eating, drinking or taking other oral medicines[2]. That shapes when breakfast happens; more in my guide to GLP-1 pills.

Low blood sugar: when it’s a real risk

The labels explain why these drugs rarely cause lows on their own: they stimulate insulin release in the presence of elevated blood glucose124. The problem comes from combining them with medicines that lower glucose even when you haven’t eaten. The NIDDK names insulin and two kinds of diabetes pills: sulfonylureas, which raise insulin over several hours, and meglitinides, taken before meals[16]. Glipizide and glimepiride are common sulfonylureas.

The US labels for Ozempic, the semaglutide tablets, Mounjaro, Victoza and Trulicity agree on the basics:

  • The risk goes up with insulin or a sulfonylurea. People using them with an insulin secretagogue (such as a sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia12345.
  • Lowering those other drugs is on the table. When starting the GLP-1 medication, prescribers should consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia12345. That’s your prescriber’s decision, not an adjustment to make on your own.
  • You should know the signs. The Ozempic and Mounjaro labels ask prescribers to tell patients on these combinations about the risk and teach them the signs and symptoms of hypoglycemia13, and both Medication Guides ask you to talk with your healthcare provider about low blood sugar and how to manage it before you start13.

The EU prescribing information adds two details. It says self-monitoring of blood glucose is needed to adjust the sulfonylurea and insulin, and recommends a stepwise approach to insulin reduction89. And the Ozempic one warns that semaglutide is not a substitute for insulin, and diabetic ketoacidosis has been reported in insulin-dependent patients whose insulin was stopped or reduced quickly when the GLP-1 medication was started[8]. The current US labels for Ozempic, the semaglutide tablets and Mounjaro are approved only for type 2 diabetes and don’t mention type 1 diabetes at all123. The Wegovy label notes that its use in type 1 diabetes or with insulin has not been evaluated[6].

These are the trial figures in section 6.1 of the US labels. “Severe” means an episode that needed another person’s help13.

In the trials Ozempic (0.5 and 1 mg)[1] Mounjaro (5, 10 and 15 mg)[3]
The drug alone Severe: 0% (30 weeks) Under 54 mg/dL: 0% at every dose vs. 1% on placebo; severe: 0% (40 weeks)
Added to a sulfonylurea Severe: 0.8% and 1.2% Under 54 mg/dL: 13.8%, 9.9% and 12.8%; severe: 0.5%, 0% and 0.6% (up to 104 weeks)
Added to basal insulin Severe: 0% and 1.5% vs. 0% on placebo; severe, or symptomatic and confirmed at 56 mg/dL or less: 8.3% and 10.7% vs. 5.3% (30 weeks) Under 54 mg/dL: 16%, 19% and 14% vs. 13% on placebo; severe: 0%, 2% and 1% vs. 0% (40 weeks)

For reference, 54 mg/dL is 3.0 mmol/L and 56 mg/dL is 3.1 mmol/L. Compare that with SURPASS-2, where 1,879 adults were taking only metformin for 40 weeks: glucose under 54 mg/dL showed up in 0.6%, 0.2% and 1.7% on tirzepatide 5, 10 and 15 mg, and in 0.4% on semaglutide 1 mg[17].

How to recognize it (and why it can be mistaken for nausea)

Both Medication Guides list the same possible signs: dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, a fast heartbeat and feeling jittery13. The EU patient leaflet for Ozempic also includes feeling sick (nausea)[8], which is also first on the list of the most common side effects of both drugs13. If you use insulin or a sulfonylurea and feel unwell, a glucose reading tells you which it is. The ADA considers a measured glucose under 70 mg/dL clinically important even without symptoms[12].

What the ADA says about treating a low

The ADA classifies hypoglycemia in three levels[12]:

  • Level 1: glucose under 70 mg/dL (3.9 mmol/L) and at or above 54 mg/dL (3.0 mmol/L).
  • Level 2: under 54 mg/dL (3.0 mmol/L).
  • Level 3: a severe event with altered mental or physical functioning that needs another person’s help, whatever the number.

For a conscious person under 70 mg/dL, glucose is the preferred treatment, although any carbohydrate that contains glucose works. “For most individuals, 15 g carbohydrates should be ingested,” with a recheck 15 minutes later and another dose if it’s still low. Foods or drinks high in fat or protein are a poor first choice: fat may slow the rise, and protein shouldn’t be used to treat a low. And insulin or a sulfonylurea still acting can bring the low back unless you eat more after recovering[12]. The NIDDK’s patient page gives 15 to 20 g, such as four glucose tablets or ½ cup (4 oz) of regular fruit juice[16]. That’s one job where juice earns its place.

That describes the guidelines, not your plan: your numbers and steps should come from your care team. The ADA also recommends that glucagon be prescribed for everyone who takes insulin or is at high risk of hypoglycemia[12].

On alcohol, the GLP-1 labels give no drinking advice. If you use insulin or a sulfonylurea, the ADA recommends checking glucose after drinking[11], and the NIDDK says it’s safer to eat something at the same time[16]. The rest is in alcohol on GLP-1 medications.

Why a slower stomach changes your blood sugar after meals

Section 12.2 of the Ozempic label explains that semaglutide delays early gastric emptying after a meal, which slows the rate at which glucose reaches the blood. After 12 weeks on semaglutide 1 mg, glucose 2 hours after a meal was 74 mg/dL lower than at baseline, a 36% relative reduction compared with placebo[1]. That’s about 4.1 mmol/L.

The Mounjaro label says tirzepatide slows post-meal glucose absorption and reduces post-meal glucose; the delay in gastric emptying is largest after the first dose and diminishes over time[3]. The EU prescribing information adds a number: across the SURPASS-1 to -5 trials, mean glucose 2 hours after meals fell by 3.35 to 4.85 mmol/L from baseline[9], roughly 60 to 87 mg/dL (my conversion).

So spikes after meals tend to be smaller, but food still counts: the ADA still asks people to limit sugary drinks, juices and refined grains[11]. And because the stomach empties more slowly, the absorption of other medicines taken by mouth may be affected13.

What to eat: where the ADA and the 2025 advisory agree

The nutrition section of the ADA Standards recommends an individualized plan built with a registered dietitian nutritionist (RDN), not a single diet[11]. Its healthy eating patterns share a core of nonstarchy vegetables, whole fruits, legumes, lean proteins, whole grains, nuts and seeds, and low-fat dairy or nondairy alternatives, with little red meat, sugar-sweetened beverages, sweets, refined grains, and processed and ultraprocessed foods[11].

The 2025 advisory points the same way and adds what changes when your appetite is small[14]:

  • Make every bite count. With much less food, the priority is not falling short on protein, vitamins and minerals[14]. The ADA also asks clinicians to monitor people losing weight for protein and micronutrient shortfalls[11]. More in vitamins and minerals when you eat little.
  • Protein first. If you fill up fast, start with the protein on your plate[14]. The protein calculator estimates your target.
  • Small meals at regular times. Without hunger it’s easy to go many hours without eating, which the advisory calls unintended intermittent fasting. It notes that intermittent fasting may increase the risk of hypoglycemia in people with type 2 diabetes on glucose-lowering drugs[14]. The NIDDK says the same about skipping or delaying meals with a sulfonylurea or insulin[15], so if you use either and are eating much less, your plan needs a review with your doctor.
  • Enough fluids, which the advisory lists among its basics[14]. Nausea, vomiting and diarrhea can dehydrate you13.

A simple tool is the diabetes plate method. On a 9-inch plate: half nonstarchy vegetables, a quarter protein and a quarter carbohydrate foods[11]. The proportion fits on a smaller plate too. The ADA cites a trial in which both the plate method and carbohydrate counting improved A1C[11]. The NIDDK notes that not everyone with diabetes needs to count carbs: if you don’t take insulin, you may not need to when using the plate, and if you do, counting helps you know how much insulin to take[15]. I adapt the plate to a small appetite in the Healthy Eating Plate on GLP-1 medications, and the weekly menu planner helps you plan the week.

Carbohydrate quality, with numbers

The ADA asks for minimally processed, high-fiber carbohydrates: at least 14 g of fiber per 1,000 kcal. It counts foods with at least 3 g of fiber per serving as higher-fiber choices[11]. On the glycemic index, it says the evidence is mixed and that a low glycemic index or load amounts to a higher-fiber eating pattern[11]. That’s why I compare carbohydrate and fiber per serving, using the food pages:

Food Serving Total carbs Fiber Protein
Lentils, cooked 150 g (5.3 oz) 30.2 g 11.9 g 13.5 g
Black beans, cooked 150 g (5.3 oz) 35.6 g 13.1 g 13.3 g
Chickpeas, cooked 150 g (5.3 oz) 41.1 g 11.4 g 13.3 g
Broccoli 150 g (5.3 oz) 10.0 g 3.9 g 4.2 g
Green beans 150 g (5.3 oz) 10.5 g 4.1 g 2.7 g
Nopales, cooked 150 g (5.3 oz) 4.9 g 3.0 g 2.0 g
Brown rice, cooked 150 g (5.3 oz) 38.4 g 2.4 g 4.1 g
White rice, cooked 150 g (5.3 oz) 42.3 g 0.6 g 4.0 g
Whole-wheat bread 40 g (1.4 oz) 17.1 g 2.4 g 5.0 g
White bread 40 g (1.4 oz) 19.8 g 1.1 g 3.5 g

Data from USDA FoodData Central; total carbs include fiber. Vegetables are raw except the nopales[19].

A serving of lentils has about 20 times the fiber of a serving of white rice and more than three times the protein. Brown rice, for all its reputation, stays under the 3 g line. If beans give you gas, start with small servings.

How much carbohydrate overall? The ADA says there’s no ideal percentage of calories from carbohydrate, protein or fat for people with diabetes. It suggests considering less carbohydrate for some adults to improve glucose, mainly by eating fewer processed foods[11]. With very-low-carbohydrate plans, it notes that insulin and other diabetes medicines may need adjusting to prevent hypoglycemia, and it advises against them for people taking SGLT2 inhibitors (such as empagliflozin or dapagliflozin) because of the risk of ketoacidosis[11]. Both are conversations for your care team before you change course.

Can I eat fruit?

Yes. The ADA includes whole fruit: fresh, frozen or canned in its own juice or without added sugar. What it asks people to replace with water or low- or no-calorie drinks is sugar-sweetened beverages, all juices included[11]. The advisory lists berries, apples, citrus, bananas and grapes among the foods to favor[14].

Fruit Serving Total carbs Fiber
Strawberries 150 g (5.3 oz) 11.5 g 3.0 g
Kiwifruit 100 g (3.5 oz) 14.7 g 3.0 g
Guava 100 g (3.5 oz) 14.3 g 5.4 g
Orange 180 g (6.3 oz) 21.2 g 4.3 g
Apple, with skin 180 g (6.3 oz) 24.8 g 4.3 g
Pear 170 g (6.0 oz) 25.8 g 5.3 g
Banana 120 g (4.2 oz) 27.4 g 3.1 g
Orange juice, fresh 200 g (7 oz, a glass) 20.8 g 0.4 g

Data from USDA FoodData Central[19].

Look at the orange: almost the same carbohydrate as the juice, but about ten times the fiber. If you use a meter or a sensor, how your glucose responds to each fruit is useful information for your care team. For sweet cravings, I have ideas in sweet cravings on Ozempic or Mounjaro.

Metformin and GLP-1 medications: similar stomach side effects

GLP-1 medications are often added to metformin. The US labels for Ozempic and Mounjaro don’t say what to do with it; the EU prescribing information says that when they’re added, the current dose of metformin can be continued89. The US metformin patient information says metformin rarely causes low blood sugar by itself; it can happen if you don’t eat enough, if you drink alcohol or if you take other medicines that lower blood sugar[10]. That first condition is worth noticing when your appetite has dropped.

Where they overlap is the gut. In a US trial of metformin, diarrhea affected 53% vs. 12% on placebo, and nausea or vomiting 26% vs. 8%[10]. These side effects generally go away after a while, and taking metformin with meals can help[10]. The ADA names bloating, abdominal discomfort and diarrhea as metformin’s main side effects and says gradual dose increases or the extended-release form can reduce them[13].

With both drugs, it’s hard to know which one causes each symptom, so tell your doctor rather than skipping meals or doses. For day-to-day relief, see my guides on nausea and constipation. One more label fact: in metformin trials of 29 weeks, vitamin B12 fell to below-normal levels in about 7% of patients[10], which the vitamins guide linked above explains.

Days with nausea, vomiting or illness

The ADA points out that illness raises the risk of both high and low blood sugar, and that the care team should assess whether you need to check more often. Clinicians should consider holding metformin when you can’t keep eating and drinking, and GLP-1 medications may need to be held during illnesses with significant digestive symptoms[12]. Those are clinical decisions, not ones to make on your own.

The Ozempic and Mounjaro Medication Guides say that diarrhea, nausea and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems; drink fluids, and tell your healthcare provider right away about nausea, vomiting or diarrhea that does not go away13. The metformin patient information lists getting dehydrated, for example from fever, vomiting or diarrhea, among the situations that raise the chance of lactic acidosis, a rare but serious complication[10]. The NIDDK adds that when you’re sick you may not be able to eat as much or keep food down, which can lower blood glucose[16].

The practical step is a sick-day plan agreed with your care team before you need it, and a same-day call if you’re vomiting repeatedly or can’t keep fluids down. More on fluids in hydration on GLP-1 medications.

What to ask your doctor, by situation

Situation What the evidence says What to ask
You use insulin or a sulfonylurea and are starting or increasing a GLP-1 medication Higher hypoglycemia risk; prescribers should consider reducing those drugs13 Should anything change? When should I check my glucose?
You eat much less than before ADA: with fixed insulin doses, keep carbohydrate consistent in timing and amount[11] Does my plan still fit what I eat now?
Nausea, sweating or shakiness Possible signs of a low138 How do I tell them apart? How do I treat a low? Should I have glucagon?
Vomiting or diarrhea that won’t stop Dehydration and kidney problems; the team weighs holding drugs1312 What’s my sick-day plan?
Metformin and stomach trouble Digestive side effects are common with both1310 Which one is it coming from?
You have diabetic retinopathy Ozempic and Mounjaro labels: monitor for progression13 Do I need more frequent eye exams?
You have gastroparesis Not recommended with severe gastroparesis13 Is this medicine right for me?
You take other oral medicines Absorption may change; Mounjaro, for the pill: switch to a non-oral contraceptive or add a barrier method for 4 weeks after starting and after each dose increase13 Does it affect any of mine?

On the eyes, section 5.3 of the Ozempic label reports that in a 2-year trial in people with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% on Ozempic vs. 1.8% on placebo; 8.2% vs. 5.2% in those with a history of retinopathy and 0.7% vs. 0.4% in those without[1]. That trial was SUSTAIN-6, with 3,297 adults (hazard ratio 1.76)[18]. Both labels explain that rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy13, and both Medication Guides ask you to report changes in vision13.

Eating very little isn’t the goal of treatment. If you have or have had an eating disorder, tell your doctor: the ADA recommends screening for disordered eating and, when it shows up, reviewing the treatment plan, ideally with a qualified professional[11]. If food, weight or glucose numbers are causing you distress, ask for help. To prepare the appointment, the doctor visit checklist lets you pick your questions and print them.

Frequently asked questions

Can Ozempic or Mounjaro cause low blood sugar?

On their own, severe lows are rare: there were none in the monotherapy trials in either US label13. The risk goes up with insulin or a sulfonylurea, which is when the labels tell the prescriber to consider reducing those drugs13.

Can I take Ozempic or Mounjaro with metformin?

It’s a common combination. The EU labels say the metformin dose can stay the same89, and in SURPASS-2, glucose under 54 mg/dL affected less than 2% of every group[17]. What adds up is the stomach side effects1013.

Do I have to count carbs?

It depends on your treatment. Counting mainly helps people on insulin know how much to take, and the plate method is a simpler option for many others1115. Decide it with your care team. On calories, see do I have to count calories on Ozempic?

Is Ozempic the same as Wegovy if I have diabetes?

Both are semaglutide, with different approved uses: Ozempic for blood sugar control in type 2 diabetes, Wegovy for weight management, among others16. Which one fits is up to your prescriber. My semaglutide guide and tirzepatide guide explain each active ingredient.

Sources

Sources consulted for this article, with the access date.

  1. Drug labelU.S. Food and Drug Administration label, via DailyMed (National Library of Medicine).Ozempic (semaglutide) injection: US Prescribing Information and Medication Guide (sections 1, 5.3, 5.5, 5.6, 5.7, 6.1, 7.1, 7.2 and 12.2), DailyMed version of June 2026.accessed .
  2. Drug labelU.S. Food and Drug Administration label, via DailyMed (National Library of Medicine).Rybelsus and Ozempic (semaglutide) tablets: US Prescribing Information (sections 1, 2.1 and 7.1), revised 1/2026.accessed .
  3. Drug labelU.S. Food and Drug Administration label, via DailyMed (National Library of Medicine).Mounjaro (tirzepatide) injection: US Prescribing Information and Medication Guide (sections 1, 5.3, 5.5, 5.6, 5.7, 6.1, 7.1, 7.2 and 12.2), revised 8/2026.accessed .
  4. Drug labelU.S. Food and Drug Administration label, via DailyMed (National Library of Medicine).Victoza (liraglutide) injection: US Prescribing Information (sections 1 and 7.2), DailyMed version of October 14, 2025.accessed .
  5. Drug labelU.S. Food and Drug Administration label, via DailyMed (National Library of Medicine).Trulicity (dulaglutide) injection: US Prescribing Information (sections 1 and 7.2), DailyMed version of June 16, 2026.accessed .
  6. Drug labelU.S. Food and Drug Administration label, via DailyMed (National Library of Medicine).Wegovy (semaglutide) injection and tablets: US Prescribing Information (sections 1 and 5.4), revised 6/2026.accessed .
  7. Drug labelU.S. Food and Drug Administration label, via DailyMed (National Library of Medicine).Zepbound (tirzepatide) injection: US Prescribing Information (sections 1 and 5.7), revised 8/2026.accessed .
  8. Drug labelEuropean Medicines Agency.Ozempic (semaglutide): EU Summary of Product Characteristics (sections 4.2 and 4.4) and package leaflet (section 4).accessed .
  9. Drug labelEuropean Medicines Agency.Mounjaro (tirzepatide): EU Summary of Product Characteristics (sections 4.1, 4.2 and 5.1).accessed .
  10. Drug labelU.S. Food and Drug Administration label, via DailyMed (National Library of Medicine).Metformin hydrochloride tablets (Zydus Pharmaceuticals USA): US Prescribing Information and Patient Information (sections 2.1, 5.1, 5.2 and 6.1), DailyMed version of July 15, 2026.accessed .
  11. Clinical guidelineAmerican Diabetes Association (Diabetes Care).American Diabetes Association Professional Practice Committee. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S89-S131 (medical nutrition therapy, recommendations 5.10 to 5.28; disordered eating, recommendations 5.50 and 5.51).accessed .
  12. Clinical guidelineAmerican Diabetes Association (Diabetes Care).American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S132-S149 (recommendations 6.15 and 6.16; hypoglycemia treatment; intercurrent illness).accessed .
  13. Clinical guidelineAmerican Diabetes Association (Diabetes Care).American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S183-S215.accessed .
  14. Clinical guidelineObesity (The Obesity Society, Wiley).Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity. 2025;33(8):1475-1503. doi:10.1002/oby.24336 (PMC12304835).accessed .
  15. InstitutionNational Institute of Diabetes and Digestive and Kidney Diseases (NIH).Healthy Living with Diabetes.accessed .
  16. InstitutionNational Institute of Diabetes and Digestive and Kidney Diseases (NIH).Low Blood Glucose (Hypoglycemia).accessed .
  17. Clinical trialNew England Journal of Medicine.Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519.accessed .
  18. Clinical trialNew England Journal of Medicine.Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141.accessed .
  19. Official databaseU.S. Department of Agriculture, Agricultural Research Service.FoodData Central (per-100 g values for each food cited in the food pages).accessed .